Your session is about to expire
← Back to Search
Empagliflozin for Kidney Disease (EMPA-PD Trial)
EMPA-PD Trial Summary
This trial studies if a drug can help reduce glucose absorption in people with end stage kidney disease who use dialysis.
EMPA-PD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEMPA-PD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 65 Patients • NCT03030222EMPA-PD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had peritonitis or an infection in my dialysis catheter recently.I have taken an SGLT2 inhibitor in the last 30 days.You have been diagnosed with Parkinson's disease for more than 3 months.Your hemoglobin level is less than 8 grams per deciliter.My peritoneal dialysis treatment plan hasn't changed recently.I am on long-term water pills for my condition.You produce more than 400 milliliters of urine in 24 hours.I have a history of severe diabetes issues in the past 6 months.I am currently on peritoneal dialysis with a working catheter.I am older than 18 years.
- Group 1: Empagliflozin or Placebo in Acute
- Group 2: Empagliflozin in Chronic
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are participating in this experiment?
"Accurately, clinicaltrials.gov shows that this research trial is currently recruiting participants. It was first publicized on March 1st 2023 and has been refreshed as recently as May 1st of the same year. The team needs to find 30 people willing to participate at a single medical site."
Has the FDA sanctioned Empagliflozin for chronic use?
"The team at Power has concluded that the safety of Empagliflozin in Chronic is a 3, as this medication is already approved and classified as a Phase 4 trial."
Are there any available slots for volunteers to participate in this clinical experiment?
"Affirmative. The information hosted on clinicaltrials.gov specifies that this medical research, which was posted initially on March 1st 2023, is actively recruiting volunteers. It needs to obtain 30 patients from a single location for the experiment to proceed further."
Share this study with friends
Copy Link
Messenger